Bristol-Myers Squibb Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Leerink Partners Remains Bullish After Opdivo and HCV Help Drive 3Q Beat for Bristol-Myers Squibb (BMY)
October 28, 2015 8:20 AM EDTLeerink Partners reiterated an Outperform rating and $77.00 Price Target on Bristol-Myers Squibb Co. (NYSE: BMY) following 3Q earnings results. Non-GAAP EPS of $0.39 beat the Street estimates of $0.35. Global revenue was $4.1B, above consensus $3.9B expectations.
Analyst Seamus Fernandez commented, "BMY reported strong 3Q:15... More
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 4c; Boosts FY15 EPS Outlook
October 27, 2015 6:59 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $0.39, $0.04 better than the analyst estimate of $0.35. Revenue for the quarter came in at $4.07 billion versus the consensus estimate of $3.83 billion.
Guidance:
Bristol-Myers Squibb sees FY2015 EPS of $1.85-$1.90, versus the consensus of... More
